Skip to content

Lenalidomide

Lenalidomide is an immunomodulatory drug primarily used in the treatment of multiple myeloma and certain other hematological disorders. It works by modulating the immune system and inhibiting angiogenesis, which can help in controlling cancer growth. Its relevance to longevity and health optimization lies in its potential to modulate immune function, which is crucial for maintaining health and preventing age-related diseases.

Intelligence Profile

Safety Profile

Lenalidomide is a medication commonly used in treating multiple myeloma and certain other hematological conditions. Here's a summary of its safety profile:

Known Side Effects

Lenalidomide is associated with several side effects. Evidence from case reports and clinical observations indicates these potential adverse effects:

  • Hematological issues: Neutropenia and thrombocytopenia are common, as the medication can affect blood cell counts.
  • Skin reactions: There is a documented case of severe plaque psoriasis exacerbation during lenalidomide maintenance therapy.
  • Gastrointestinal symptoms: These may include nausea and diarrhea.
  • Other possible effects: Fatigue, rash, and fever have also been noted in various studies.

Contraindications

Specific contraindications for lenalidomide were not comprehensively detailed in the evidence provided. However, it is typically contraindicated in pregnancy due to the risk of severe fetal harm, a general warning well-established for lenalidomide-related therapies.

Drug Interactions

The evidence did not explicitly cover drug interactions, although lenalidomide is known to interact with medications such as certain statins and anti-clotting agents outside this dataset. Caution with concurrent therapies is advised, particularly those affecting the immune system or hematopoiesis.

Populations to Avoid Use

  • Pregnancy: As previously mentioned, lenalidomide is contraindicated in pregnant individuals due to teratogenic effects.
  • Severe uncontrolled infections: Due to immunosuppressive effects, those with active severe infections should typically avoid lenalidomide.

There are no specific recent studies provided that further define populations that should avoid lenalidomide beyond general clinical practice guidelines not central to the studies cited.

Disclaimer

This overview is based on available evidence and may not include the full scope of considerations required for prescribing lenalidomide. Always consult a healthcare professional for medical advice tailored to personal health conditions.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.